Metropolitan Life Insurance Co. NY reduced its stake in shares of Omeros Corporation (NASDAQ:OMER) by 1.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,622 shares of the biopharmaceutical company’s stock after selling 456 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Omeros Corporation were worth $418,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in OMER. Bank of New York Mellon Corp raised its position in shares of Omeros Corporation by 2.8% in the first quarter. Bank of New York Mellon Corp now owns 225,583 shares of the biopharmaceutical company’s stock worth $3,411,000 after buying an additional 6,043 shares during the period. Sheaff Brock Investment Advisors LLC raised its position in shares of Omeros Corporation by 21.7% in the first quarter. Sheaff Brock Investment Advisors LLC now owns 28,000 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 5,000 shares during the period. Chicago Equity Partners LLC purchased a new position in shares of Omeros Corporation during the first quarter worth $639,000. Nwam LLC raised its position in shares of Omeros Corporation by 0.5% in the first quarter. Nwam LLC now owns 44,790 shares of the biopharmaceutical company’s stock worth $677,000 after buying an additional 232 shares during the period. Finally, Wells Fargo & Company MN raised its position in shares of Omeros Corporation by 5.5% in the first quarter. Wells Fargo & Company MN now owns 37,717 shares of the biopharmaceutical company’s stock worth $571,000 after buying an additional 1,960 shares during the period. Hedge funds and other institutional investors own 43.94% of the company’s stock.

Omeros Corporation (OMER) traded up 0.333% during trading on Wednesday, reaching $22.595. The company’s stock had a trading volume of 337,418 shares. Omeros Corporation has a 12 month low of $7.20 and a 12 month high of $27.09. The stock’s 50 day moving average is $21.41 and its 200 day moving average is $16.46. The company’s market cap is $1.01 billion.

Omeros Corporation (NASDAQ:OMER) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.12. The firm had revenue of $17.15 million during the quarter, compared to analysts’ expectations of $14.63 million. During the same quarter in the previous year, the company posted ($0.32) EPS. Omeros Corporation’s revenue for the quarter was up 71.5% on a year-over-year basis. On average, equities analysts expect that Omeros Corporation will post ($1.24) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Omeros Corporation (OMER) Shares Sold by Metropolitan Life Insurance Co. NY” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/omeros-corporation-omer-shares-sold-by-metropolitan-life-insurance-co-ny/1494922.html.

A number of brokerages have recently weighed in on OMER. Maxim Group reiterated a “buy” rating and set a $24.00 target price (up previously from $23.00) on shares of Omeros Corporation in a research note on Tuesday, August 8th. Zacks Investment Research upgraded Omeros Corporation from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub lowered Omeros Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, June 28th. WBB Securities reiterated a “strong-buy” rating and set a $75.00 target price on shares of Omeros Corporation in a research note on Wednesday, June 14th. Finally, Wedbush reiterated an “outperform” rating and set a $47.00 target price on shares of Omeros Corporation in a research note on Wednesday, June 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $32.80.

In related news, VP Michael A. Jacobsen sold 12,000 shares of the company’s stock in a transaction that occurred on Friday, June 16th. The stock was sold at an average price of $24.95, for a total value of $299,400.00. Following the transaction, the vice president now owns 19,500 shares in the company, valued at $486,525. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Michael A. Jacobsen sold 24,000 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $21.20, for a total value of $508,800.00. Following the completion of the transaction, the vice president now owns 2,650 shares in the company, valued at approximately $56,180. The disclosure for this sale can be found here. 13.60% of the stock is currently owned by corporate insiders.

About Omeros Corporation

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Want to see what other hedge funds are holding OMER? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omeros Corporation (NASDAQ:OMER).

Institutional Ownership by Quarter for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.